ATE206053T1 - Verwendung von monosialogangliosid gml oder von n-dichlor-acetyl-lyso-gml zur vorbeugung oder zur umkehrung der von einer langzeitbehandlung mit l- dopa bei der therapie von morbus parkinson induzierten neuronale degeneration - Google Patents
Verwendung von monosialogangliosid gml oder von n-dichlor-acetyl-lyso-gml zur vorbeugung oder zur umkehrung der von einer langzeitbehandlung mit l- dopa bei der therapie von morbus parkinson induzierten neuronale degenerationInfo
- Publication number
- ATE206053T1 ATE206053T1 AT96116051T AT96116051T ATE206053T1 AT E206053 T1 ATE206053 T1 AT E206053T1 AT 96116051 T AT96116051 T AT 96116051T AT 96116051 T AT96116051 T AT 96116051T AT E206053 T1 ATE206053 T1 AT E206053T1
- Authority
- AT
- Austria
- Prior art keywords
- gml
- dopa
- parkinson
- therapy
- disease
- Prior art date
Links
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 title abstract 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 title abstract 2
- 208000018737 Parkinson disease Diseases 0.000 title abstract 2
- 238000011866 long-term treatment Methods 0.000 title abstract 2
- 230000004770 neurodegeneration Effects 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- CQCBGDOXLXRPIU-WUKNDPDISA-N 5-acetamido-2-[5-[3-acetamido-5-hydroxy-6-(hydroxymethyl)-4-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-2-[6-[(e)-2-[(2,2-dichloroacetyl)amino]-3-hydroxyoctadec-4-enoxy]-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-3-hydroxy-6-(hydroxyme Chemical compound OC1C(O)C(OCC(C(O)/C=C/CCCCCCCCCCCCC)NC(=O)C(Cl)Cl)OC(CO)C1OC1C(O)C(OC2(OC(C(NC(C)=O)C(O)C2)C(O)C(O)CO)C(O)=O)C(OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)NC(C)=O)C(CO)O1 CQCBGDOXLXRPIU-WUKNDPDISA-N 0.000 abstract 1
- QPJBWNIQKHGLAU-IQZHVAEDSA-N ganglioside GM1 Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 QPJBWNIQKHGLAU-IQZHVAEDSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI920591A IT1254280B (it) | 1992-03-13 | 1992-03-13 | Composizioni farmaceutiche comprendenti monosialoganglioside gm1 o un suo derivato atte al trattamento della malattia di parkinson |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE206053T1 true ATE206053T1 (de) | 2001-10-15 |
Family
ID=11362423
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT96116051T ATE206053T1 (de) | 1992-03-13 | 1993-03-12 | Verwendung von monosialogangliosid gml oder von n-dichlor-acetyl-lyso-gml zur vorbeugung oder zur umkehrung der von einer langzeitbehandlung mit l- dopa bei der therapie von morbus parkinson induzierten neuronale degeneration |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6620792B1 (de) |
| EP (2) | EP0630250A1 (de) |
| JP (1) | JP2872809B2 (de) |
| AT (1) | ATE206053T1 (de) |
| DE (1) | DE69330842T2 (de) |
| ES (1) | ES2161953T3 (de) |
| IT (1) | IT1254280B (de) |
| WO (1) | WO1993017691A2 (de) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1259176B (it) * | 1992-10-23 | 1996-03-11 | Fidia Spa | Composizioni farmaceutiche comprendenti monosialoganglioside gm1 (o suo derivato) e fattore neuronotrofico ciliare (cntf) atte al trattamento di patologie del sistema nervoso |
| JP2005527467A (ja) * | 2001-08-29 | 2005-09-15 | ネオーズ テクノロジーズ， インコーポレイテッド | 新規な合成ガングリオシド誘導体およびその組成物 |
| EP1358910A1 (de) * | 2002-05-02 | 2003-11-05 | B.R.A.H.M.S Aktiengesellschaft | Verfahren und Mittel zur Prävention, Hemmung und Therapie von Krebserkrankungen |
| EP1367395A1 (de) | 2002-05-02 | 2003-12-03 | B.R.A.H.M.S Aktiengesellschaft | Diagnose von Neoplasmen mit Hilfe von anti-Gangliosid-Antikörpern |
| US7943750B2 (en) * | 2007-06-18 | 2011-05-17 | Laboratoire Medidom S.A. | Process for obtaining pure monosialoganglioside GM1 for medical use |
| CN101732331B (zh) * | 2008-11-20 | 2012-05-23 | 北京四环制药有限公司 | 一种单唾液酸四己糖神经节苷脂钠与谷氨酸的组合物 |
| US9463186B2 (en) | 2013-04-15 | 2016-10-11 | Northwestern University | Treatment for dopaminergic disorders |
| CN104490837A (zh) * | 2014-12-30 | 2015-04-08 | 哈尔滨医科大学科技开发总公司 | 单唾液酸四己糖神经节苷脂钠的口服制剂 |
| RU2632710C2 (ru) * | 2016-03-31 | 2017-10-09 | Лонг Шенг Фарма Лимитед | Способ получения натрий моносиалового ганглиозида и нейропротекторное средство на его основе |
| CN108815131B (zh) * | 2018-09-11 | 2021-01-01 | 四川奇格曼药业有限公司 | 一种神经节苷脂缓释片及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1199116B (it) | 1984-07-03 | 1988-12-30 | Fidia Farmaceutici | Derivati di gangliosidi |
| IT1208751B (it) * | 1986-06-30 | 1989-07-10 | Fidia Farmaceutici | Possibile uso dei gangliosidi esogeni in malattie tumorali come fattore protettivo contro la neurotossicita' da farmaci antitumorali |
| IT1235161B (it) * | 1988-12-02 | 1992-06-22 | Fidia Farmaceutici | Derivati di lisogangliosidi |
| IT1249034B (it) * | 1990-06-29 | 1995-02-11 | Fidia Spa | Impiego del monosialoganglioside gm1 e del suo derivato estere interno per impedire l'instaurarsi della tolleranza nell'uomo all'effetto analgesico della morfina e analoghi |
| IT1253832B (it) * | 1991-08-01 | 1995-08-29 | Fidia Spa | Derivati di gangliosidi |
-
1992
- 1992-03-13 IT ITMI920591A patent/IT1254280B/it active
-
1993
- 1993-03-12 EP EP93906509A patent/EP0630250A1/de not_active Withdrawn
- 1993-03-12 AT AT96116051T patent/ATE206053T1/de not_active IP Right Cessation
- 1993-03-12 WO PCT/EP1993/000571 patent/WO1993017691A2/en not_active Ceased
- 1993-03-12 EP EP96116051A patent/EP0770389B1/de not_active Expired - Lifetime
- 1993-03-12 JP JP5515350A patent/JP2872809B2/ja not_active Expired - Fee Related
- 1993-03-12 DE DE69330842T patent/DE69330842T2/de not_active Expired - Lifetime
- 1993-03-12 ES ES96116051T patent/ES2161953T3/es not_active Expired - Lifetime
-
1994
- 1994-09-12 US US08/304,391 patent/US6620792B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP0770389B1 (de) | 2001-09-26 |
| IT1254280B (it) | 1995-09-14 |
| ES2161953T3 (es) | 2001-12-16 |
| ITMI920591A0 (it) | 1992-03-13 |
| WO1993017691A2 (en) | 1993-09-16 |
| JPH07508258A (ja) | 1995-09-14 |
| US6620792B1 (en) | 2003-09-16 |
| DE69330842T2 (de) | 2002-04-04 |
| DE69330842D1 (de) | 2001-10-31 |
| JP2872809B2 (ja) | 1999-03-24 |
| ITMI920591A1 (it) | 1993-09-13 |
| EP0630250A1 (de) | 1994-12-28 |
| WO1993017691A3 (en) | 1993-11-11 |
| EP0770389A1 (de) | 1997-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE59107331D1 (de) | Flupirtin in Kombination mit Antiparkinsonika zur Bekämpfung von Muskelverspannungen | |
| DE69129082D1 (de) | Vom Stoffwechselbedarf gesteuerter taktanpassender Schrittmacher | |
| DE3779149D1 (de) | Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit. | |
| DE3885574D1 (de) | Durch körperliche Aktivität gesteuerter Herzschrittmacher. | |
| DK0768312T3 (da) | Anvendelse af K-252a-derivater til at forbedre funktionen af en striatal neuron | |
| BR8804188A (pt) | Processo para controlar a aspereza da superficie de um filme | |
| DK90089A (da) | Hudbehandlingspraeparat | |
| ATE206053T1 (de) | Verwendung von monosialogangliosid gml oder von n-dichlor-acetyl-lyso-gml zur vorbeugung oder zur umkehrung der von einer langzeitbehandlung mit l- dopa bei der therapie von morbus parkinson induzierten neuronale degeneration | |
| IT1221826B (it) | Preparato per uso topico per il trattamento terapeutico dell impotentia coeundi | |
| IT8048692A0 (it) | Metodo terapeutico per il trattamento del diabete mellito a insorgenza giovanile e composizione farmaceutica per tale metodo | |
| IT1212143B (it) | Composizione ad attivita'tricogena. | |
| PT89249A (pt) | Processo para a preparacao de novos derivados de piperidinilo 1,4-dissubstituido com actividade terapeutica | |
| ES542997A0 (es) | Autoclave para el tratamiento de licor de cacao | |
| IT8721115A0 (it) | Fitopreparato per la cura di affezioni cutanee. | |
| FI873429A7 (fi) | Silmälääketieteelliset koostumukset hermodegeneraatioiden hoitoon. | |
| DE69007065D1 (de) | Verwendung von Diadenosin-5',5'''-p1,p4-tetraphosphat zur Herstellung eines Arzneimittels zur Behandlung von Herzkrankheiten. | |
| ATE162717T1 (de) | Behandlung kardialer dysfunktion mit 15- ketoprostaglandinderivaten | |
| DE3885573D1 (de) | Durch körperliche Aktivität gesteuerter Herzschrittmacher. | |
| DK671187A (da) | Anvendelse af 5-aryl-3h-1,2,4-triazol-3-oner ved behandling af neurodegenerative sygdomme | |
| DK526985A (da) | Polycykliske biocide forbindelser, deres fremstilling og mellemprodukter herved samt deres anvendelse i medicinske praeparationer | |
| FI874450A7 (fi) | Farmaseuttiset valmisteet alkuperältään toiminnallisten ja elimelliste n aivohäiriöiden hoitamiseen. | |
| FI873727A7 (fi) | Terebraaliseen iskemiaaseen liittyvien häiriöiden hoitoon tarkoitettu terapeuttinen aine. | |
| ES516605A0 (es) | "procedimiento para la produccion o tratamiento de ferrocromo". | |
| ZA897549B (en) | Medicament for the treatment of diseases caused by retroviruses | |
| ZA87378B (en) | Means for treating coronary diseases or organic brain syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |